Skip to main content

Table 3 Comparison of the economic and clinical outcomes according to carbapenem susceptibility of infecting organism

From: Economic and clinical burden from carbapenem-resistant bacterial infections and factors contributing: a retrospective study using electronic medical records in Japan

Variables CS infections (N = 9431) CR infections (N = 86) P-value
Death, n (%) 2062 (21.9) 22 (25.6) 0.407
Length of hospital stay (days), median (IQR)
 Total 46 (29–74) 64 (39–99)  < 0.001
 Before culture test 13 (6–25) 24 (10–57)  < 0.001
 After culture test 27 (15–50) 30 (16–67) 0.132
Cost (USD), median (IQR)   
 Total 20,077 (12,670–33,345) 27,501 (17,186–48,980)  < 0.001
 Inter-consultations 143 (80–244) 163 (96–312) 0.238
 Medications 1609 (736–3,571) 3477 (1585–9716)  < 0.001
 Surgical procedures 2327 (362–9,377) 3761 (572–12,239) 0.196
 Laboratory tests 1845 (1185–2930) 2498 (1666–4640) 0.002
 Hospital stay 10,560 (6789–16,304) 14,307 (9790–22,471)  < 0.001
  1. CR carbapenem-resistant, CS carbapenem-susceptible; IQR interquartile range, USD U.S. dollar (1 USD = 110 JPY, 2021); SD standard deviation